BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

ZLB Behring

ZLB Behring is one of the world’s leading pharmaceutical companies specializing in the manufacture of plasma products. Its comprehensive line of therapies include products for the treatment of hemophilia and other coagulation disorders, immunoglobulins for the prevention and treatment of immune disorders, treatments that inhibit the formation of blood clots, wound-healing agents used during major surgical procedures, and plasma expanders for the treatment of a variety of conditions such as shock, burns and circulatory disorders. Additionally, ZLB Behring operates one of the world’s largest, fully-owned plasma collection networks.Both ZLB Behring and its Australian parent company CSL can look back on a long history of saving lives. CSL was set up in 1916, with the aim of supplying the population of Australia and New Zealand with vaccines.Three major companies form what is now known as ZLB Behring: ZLB, Behringwerke, and Armour. ZLB had been set up in 1949 as a department of the Swiss Red Cross. In 1904, Emil von Behring created Behringwerke in Marburg, Germany, to produce sera and vaccines to cure infectious diseases. In 1885, Armour Pharmaceutical Company began to produce pepsin, an enzyme aiding digestion. 1885 Armour Pharmaceutical produces Pepsin, an enzyme to aid digestion.


Contact Details:
P.O. Box 61501 1020 First Avenue
King of Prussia
Pennsylvania
19406
United States of America
Tel:610-878-4000
Fax:610-878-4009
Email:webmaster.us@zlbbehring.com
WWW:

www.zlbbehring.com/




Loading...

Recent Publications by ZLB Behring:

Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
INTRODUCTION: Prothrombin complex concentrate (PCC) is recommended for...
12th December, 2007
ZLB Behring GmbH, D-35002 Marburg, Germany. Thromb Res. 2007;119(5):643-51. Epub 2006 Jul 13.
DOI Direct Link
Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
Patients with immunodeficiencies or some types of autoimmune diseases rely...
15th September, 2007
ZLB Behring AG, Wankdorfstr. 10, CH-3000 Bern 22, Switzerland. Biologicals. 2007 Mar;35(1):35-42. Epub 2006 Apr 3.
DOI Direct Link
Prevention of gynaecological adhesions using haemostatic fleece in a rabbit model.
This pre-clinical study was performed to investigate the ability of the...
14th March, 2007
ZLB Behring GmbH, J Int Med Res. 2006 Sep-Oct;34(5):505-13.
Stability of Beriplast P fibrin sealant: storage and reconstitution.
This study was performed to investigate the stability of Beriplast P...
20th October, 2006
ZLB Behring GmbH, P.O. Box 1230, 35002 Marburg, Germany. Int J Pharm. 2006 Apr 26;313(1-2):1-4. Epub 2006 Mar 10.
DOI Direct Link
Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin.
Intravenous immunoglobulin (IVIG) preparations are derived from the pooled...
27th June, 2006
ZLB Behring AG, Wankdorfstrasse 10, 3000 Bern 22, Switzerland. Ann N Y Acad Sci. 2005 Jun;1051:582-90.
DOI Direct Link

View more ZLB Behring research publications.

BioNews Results for ZLB Behring:

ZLB Plasma Licenses Mediware's RecruitTrak(TM) for 65 Facilities
Genetic Engineering News:  Sep 30 2008 8:52AM Matching: zlb behring
Trust Digital Provides HIPAA Security for CSL Behring's HeliTrax System
Genetic Engineering News:  Sep 15 2008 1:27PM Matching: zlb behring
Trust Digital Provides HIPAA Security for CSL Behring's HeliTrax System
Pharma Live:  Sep 15 2008 9:48PM Matching: zlb behring

ZLB Behring Patents:

US Patent No.Title
7399471 Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
6835817 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
6874657 Biological sealant storage and dispensing system
6884616 DNA-construct for the tissue-specific expression of a blood coagulation factor
6911334 Protease for activating clotting factor VII

View more ZLB Behring patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 271 times since April 2007, the link to the organisation's website has been followed 76 times

Recent Search Terms used to find this page: behringwerke csi | ZLB Behring | average wholesale price for Privigen | privigen | .

Search for more companies in King of Prussia

Search for more companies in Pennsylvania



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ZLB Behring
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.